PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)

STATUS

Recruiting
participants needed

80
sponsor

BioNTech RNA Pharmaceuticals GmbH

Send

Updated on 19 February 2024

See if I qualify

HIV Infection

corticosteroids

antibiotics

epinephrine

bladder cancer

metastasis

docetaxel

cancer vaccine

adenocarcinoma

luteinizing hormone

prednisone

immunosuppressive agents

carcinoma

major surgery

chronic obstructive pulmonary disease

gonadotropin releasing hormone

systemic therapy

gonadotropin

testosterone

goserelin

urinary tract infection

prostatectomy

abiraterone

lung disease

enzalutamide

cabazitaxel

hepatitis c

serum testosterone

saw palmetto

adenocarcinoma of prostate

gonadotrophin

gonadorelin

adrenal

squamous cell carcinoma of the skin

luteinising hormone

Summary

Open-label, multicenter, dose titration and expansion three-arm trial to evaluate the safety, tolerability, immunogenicity, and preliminary efficacy of W_pro1 cancer vaccine (W_pro1) in patients with metastatic castration resistant prostate cancer (mCRPC) W_pro1 in combination with goserelin acetate with or without cemiplimab, in patients with high-risk, localized prostate cancer (LPC)

Description

W_pro1 consists of messenger ribonucleic acid (mRNA [or RNA]) targeting 5 antigens expressed in de novo and metastatic prostate cancer that are separately complexed with liposomes to form serum-stable RNA lipoplexes (RNA-LPX).
- The RNA molecules are immune-pharmacologically optimized for high stability, translational efficiency and presentation on major histocompatibility complex (MHC) class I and II molecules. The vaccine is intended for intravenous (IV) bolus injection.
- The RNA-LPX cancer vaccine induces activation of both the adaptive immune system (vaccine antigen-specific CD8+/CD4+ T cell) as well as the innate immune system (TLR7 agonism of single-stranded RNA). The physiology of efficient induction, expansion and differentiation of antigen-specific T cells is associated with programmed death receptor-1 (PD-1) upregulation on these T cells. Thus, the cancer vaccine is expected to have a synergistic mechanism of action with anti-PD-1.
- In summary, the mechanism of action of W_pro1 both in monotherapy and in combination with anti-PD-1 immune checkpoint inhibitor cemiplimab, together with carefully selected and refined clinical setting presents a unique opportunity for patients with different stages of prostate cancer.

Details

Condition	Malignant neoplasm of prostate, Prostatic disorder
Age	18years - 100years
Treatment	Cemiplimab, W_pro1, Goserelin acetate
Clinical Study Identifier	NCT04382898
Sponsor	BioNTech RNA Pharmaceuticals GmbH
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	b'Main inclusion criteria:'
	b'Patients must be male and aged \\u226518 years.'
	b'Patients must have histologically confirmed prostate adenocarcinoma.'
	b'Patients must have an Eastern Cooperative Oncology Group Performance Status score of 0'
	b'or 1.'
	b'Specific key inclusion criteria for mCRPC patients:'
	b'Patients must have histologically confirmed mCRPC and have progressed after at least 2'
	b'but no more than 3 lines of life-prolonging systemic therapy (e.g., abiraterone or'
	b'enzalutamide, docetaxel, cabazitaxel) or cannot tolerate or have refused any of these'
	b'therapies. These lines of therapy include life-prolonging therapies administered in'
	b'the metastatic hormone-sensitive setting.'
	b'Prior surgical or chemical castration with a serum testosterone <1.7 nmol/L (50'
	b'ng/dL). If the method of castration is luteinizing hormone-releasing hormone analogue'
	b'(LHRHa), there must be a plan to maintain effective LHRHa therapy for the duration of'
	b'the trial.'
	b'Patients must have documented mCRPC progression within 6 months prior to screening'
	b'(assuming no subsequent change in treatments), as determined by the investigator.'
	b'Patients must agree to provide an archival pre-treatment formalin-fixed,'
	b'paraffin-embedded tumor sample if available.'
	b'Specific key inclusion criteria for newly diagnosed LPC patients:'
	b'Treatment-na\\xefve patients with high-risk LPC (ie, N0, M0) defined according to European'
	b'Association of Urology Guidelines on Prostate Cancer (2018). Patients must have at'
	b'least 1 of the following:'
	b'PSA >20 ng/mL or'
	b'Gleason Score >7 or'
	b'Localized stage \\u2265cT2b, N0, M0 according to tumor, node, metastasis'
	b'classification.'
	b'Patients who intend to have and are suitable for a radical prostatectomy.'
	b'Patients must agree to provide tumor sample(s) from pre-treatment diagnostic biopsy'
	b'and planned post-treatment surgery.'
	b'Main exclusion criteria for all patients:'
	b'Patients with uncontrolled intercurrent illness.'
	b'Patients with a known history or current malignancy other than the inclusion'
	b'diagnosis. Note: Patients with non-invasive basal cell or squamous cell skin'
	b'carcinoma, non-invasive, superficial bladder cancer, and any cancer with a complete'
	b'response (CR) that lasted more than 2 years may be included.'
	b'Patients who have had major surgery (e.g., requiring general anesthesia) within 4'
	b'weeks before screening, or have not fully recovered from surgery, or have a surgery'
	b'planned during the time of trial participation, except for the radical prostatectomy'
	b'planned for patients in Part 2 Arms 2 and 3.'
	b'Patients who have a known history of any of the following (testing not required):'
	b'Human immunodeficiency virus (HIV) 1 or 2'
	b'Hepatitis B (carrier or active infection)'
	b'Hepatitis C (unless considered cured 5 years post curative anti-viral therapy)'
	b'Patients who have received or currently receive the following therapy/medication:'
	b'Chronic systemic immunosuppressive corticosteroid treatment (prednisone >5 mg'
	b'daily orally [PO] or IV, or equivalent) during the trial. Note: Replacement'
	b'therapy (e.g., physiologic corticosteroid replacement therapy for adrenal or'
	b'pituitary insufficiency) is not considered a form of systemic treatment and is'
	b'permitted.'
	b'Prior treatment with other immune modulating agents for any non-cancer disease'
	b'within 4 weeks or 5 half-lives of the agent (whichever is shorter) before the'
	b'first dose of investigational medicinal product (IMP).'
	b'Prior treatment with live-attenuated vaccines within 4 weeks before the first'
	b'dose of IMP during treatment, and for 3 months after the last dose of W_pro1.'
	b'Prior treatment with an investigational drug (including investigational vaccines)'
	b'within 4 weeks or 5 half-lives of the agent (whichever is shorter) before the'
	b'planned first dose of IMP.'
	b'Therapeutic PO or IV antibiotics within 14 days prior to enrollment. Note:'
	b'Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary'
	b'tract infection or chronic obstructive pulmonary disease) may be enrolled.'
	b'Concurrent use of herbal products that may decrease PSA levels (e.g., saw'
	b'palmetto).'
	b'Specific key exclusion criteria for mCRPC patients:'
	b'Excluded medical conditions'
	b'Patients with toxicities from previous anti-cancer therapies that have not resolved to'
	b'baseline levels or to Grade 1 or less according to National Cancer Institute (NCI)'
	b'Common Terminology Criteria for Adverse Events (CTCAE) v5.0 with the exception of'
	b'alopecia, anorexia, vitiligo, fatigue, hyperthyroidism, hypothyroidism, and peripheral'
	b'neuropathy. Anorexia, hyperthyroidism, hypothyroidism, and peripheral neuropathy must'
	b'have recovered to \\u2264Grade 2.'
	b'Patients with clinically active brain metastases.'
	b'Patients with a history of symptomatic metastatic brain or meningeal tumors may'
	b'be included, if the end of definitive therapy is >3 months before the first dose'
	b'of W_pro1 and the patients have no clinical or radiological evidence of tumor'
	b'growth.'
	b'Patients with brain metastases must not be undergoing acute or chronic'
	b'corticosteroid therapy or steroid taper.'
	b'Patients with central nervous system symptoms should undergo a computed'
	b'tomography scan or magnetic resonance imaging (MRI) of the brain to exclude new'
	b'or progressive brain metastases. Spinal cord metastasis is acceptable. However,'
	b'patients with spinal cord compression should be excluded.'
	b'Excluded prior or concomitant anti-cancer therapies'
	b'Patients who have received or currently receive the following anti-cancer'
	b'therapy/agent:'
	b'Prior radiation therapy with curative intent within 14 days before the first dose'
	b'of IMP. Note: Palliative radiotherapy is allowed.'
	b'Prior treatment with an anti-cancer agent (within 4 weeks or for systemic'
	b'therapies after at least 5 half-lives of the drug [whichever is shorter] before'
	b'the first dose of IMP). Note: Prior treatment with bone resorptive therapy, such'
	b'as bisphosphonates (e.g., pamidronate, zoledronic acid, etc.) and denosumab, is'
	b'allowed assuming that the patients have been on stable doses for \\u22654 weeks prior'
	b'to first dose of trial treatment.'
	b'Prior treatment with anti-cancer immunomodulating agents, such as blockers of'
	b'PD-1, programmed cell death 1 ligand 1 (PD-L1), tumor necrosis factor receptor'
	b'uperfamily member 9 (TNRSF9, 4-1BB, CD137), tumor necrosis factor receptor'
	b'uperfamily member 4 (OX-40), therapeutic vaccines, cytokine treatments, or any'
	b'investigational agent within 4 weeks before the first dose of IMP.'

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

I am at least 18 years old.

By sending a message, I agree to share my information with the study team for the selected site and consent to receive emails and text messages for trial updates, notifications, and related communication. TrialX values your privacy; your information will be handled in accordance with our Privacy Policy

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

immunosuppressive agents

carcinoma

major surgery

chronic obstructive pulmonary disease

gonadotropin releasing hormone

urinary tract infection

adenocarcinoma of prostate

gonadotrophin

gonadorelin

adrenal

squamous cell carcinoma of the skin

luteinising hormone

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)